Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients.
Assessment of pancreatic neuroendocrine tumor cytologic genotype diversity to guide personalized medicine using a custom gastroenteropancreatic next-generation sequencing panel.
Oncotarget
Gleeson, Ferga C FC; Voss, Jesse S JS; Kipp, Benjamin R BR; Kerr, Sarah E SE; Van Arnam, John S JS; Mills, John R JR; Marcou, Cherisse A CA; Schneider, Amber R AR; Tu, Zheng Jin ZJ; Henry, Michael R MR; Levy, Michael J MJ